CVI Holdings’s Estrella Immunopharma Warrant ESLAW Stock Holding History

CVI Holdings’s Portfolio ESLAW Stock Details ESLAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-86,040	Closed	-$4.78K	–	239
2023 Q2	$4.78K	Sell	86,040 -100	-0.1%	-$7	0.01%	197
2023 Q1	$8.81K	Sell	86,140 -20	-0%	-$1	﹤0.01%	272
2022 Q4	$4.48K	Sell	86,160 -640	-0.7%	-$54	﹤0.01%	455
2022 Q3	$6K	Hold	86,800	–	–	﹤0.01%	681
2022 Q2	$27K	Sell	86,800 -700	-0.8%	-$155	﹤0.01%	588
2022 Q1	$20K	Hold	87,500	–	–	﹤0.01%	775
2021 Q4	$44K	Hold	87,500	–	–	﹤0.01%	802
2021 Q3	$36K	Buy	+87,500	New	+$35.9K	﹤0.01%	799

Other funds holding ESLAW

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

ASM

ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

CVI Holdings's ESLAW Position: Q3 2023 in Review

CVI Holdings sold out of Estrella Immunopharma Warrant (ESLAW) in Q3 2023, closing a stake of 86,040 shares — an estimated $4.78K sold.

CVI Holdings first reported a position in ESLAW in Q3 2021 and held it in 8 quarters. The position peaked at $44K in Q4 2021. 11 funds tracked by Wall St. Rank hold ESLAW as of Q3 2023.

CVI Holdings reported no remaining Estrella Immunopharma Warrant position as of Q3 2023 after selling out during the quarter.
CVI Holdings sold 86,040 Estrella Immunopharma Warrant shares in Q3 2023, an estimated $4.78K.
CVI Holdings first reported a position in Estrella Immunopharma Warrant in Q3 2021 and held it in 8 quarters.
CVI Holdings's Estrella Immunopharma Warrant position peaked at $44K in Q4 2021.
11 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q3 2023.

Based on CVI Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.